Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Lymphoid 1

Conditions

Primary Myelofibrosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Myeloproliferative Disorders 1Myelodysplastic Syndromes 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Acute 1

Interventions

Specimen Handling 267Magnetic Resonance Spectroscopy 218pembrolizumab 203Carboplatin 170Cisplatin 137Biopsy 136Cyclophosphamide 131Paclitaxel 120Nivolumab 110Bevacizumab 104Gemcitabine 102Radiotherapy 85Dexamethasone 77Pemetrexed 75atezolizumab 73Fluorouracil 71fludarabine 69Doxorubicin 68Leucovorin 66Docetaxel 66Radiation 65Oxaliplatin 62Rituximab 60venetoclax 58Prednisone 58Cetuximab 54durvalumab 53Vincristine 52Etoposide 51130-nm albumin-bound paclitaxel 51

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
itacitinib × 30 days × Clear all
NCT05364762 2026-06-03

Adding Itacitinib to Cyclophosphamide and Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Hematopoietic Stem Cell Transplants

City of Hope Medical Center

Phase 2 Active not recruiting
20 enrolled
LymphoidMyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡